Need help finding what you are looking for?
Contact Us
PUBLISHER: FirstWord Group | PRODUCT CODE: 1524358
PUBLISHER: FirstWord Group | PRODUCT CODE: 1524358
Non-Hodgkin Lymphoma - KOL Insight
PUBLISHED: annual subscription
PAGES:
DELIVERY TIME:
SELECT AN OPTION
This Non-Hodgkin's Lymphoma (NHL) Therapy Trends report provides a detailed analysis of current and emerging therapies. It includes insights from leading Key Opinion Leaders (KOLs) on the efficacy and future potential of CAR T-cell therapy, bispecific antibodies, and BTK inhibitors. The report examines the latest trends, challenges, and advancements in NHL treatment, offering valuable information for healthcare professionals and researchers. It aims to inform on the evolving landscape of NHL management, supported by data-driven findings and expert opinions.
Table of Contents
Executive summary
Current and future treatment algorithms
Research objectives
CAR T-cell therapies
- Diffuse large B-cell lymphoma
- Yescarta (axicabtagene ciloleucel; Gilead), Breyanzi (lisocabtagene maraleucel; BMS) and Kymriah (tisagenlecleucel; Novartis)
- Follicular lymphoma
- Yescarta (axicabtagene ciloleucel; Gilead), Breyanzi (lisocabtagene maraleucel; BMS) and Kymriah (tisagenlecleucel; Novartis)
- Mantle cell lymphoma
- Tecartus (brexucabtagene autoleucel; Gilead) and Breyanzi (lisocabtagene maraleucel; BMS)
- Next-generation CAR T-cell therapies
- Key insights summary
T cell-engaging bispecific antibodies (BsAbs)
- Follicular lymphoma
- Lunsumio (mosunetuzumab; Roche), Epkinly/Tepkinly (epcoritamab; AbbVie/Genmab), Columvi (glofitamab; Roche) and odronextamab (Regeneron)
- Diffuse large B-cell lymphoma
- Epkinly/Tepkinly (epcoritamab; AbbVie/Genmab), Columvi (glofitamab; Roche), Lunsumio (mosunetuzumab; Roche), and odronextamab (Regeneron)
- Mantle cell lymphoma and marginal zone lymphoma
- Epkinly/Tepkinly (epcoritamab; AbbVie/Genmab), Columvi (glofitamab; Roche), Lunsumio (mosunetuzumab; Roche) and odronextamab (Regeneron)
Antibody-drug conjugates (ADCs)
- Approved drugs
- Polivy (polatuzumab vedotin; Roche)
- Zynlonta (loncastuximab tesirine; ADC Therapeutics/Sobi)
Monoclonal antibodies (mAbs)
- Approved drugs
- Monjuvi/Minjuvi (tafasitamab; Incyte)
BCL-2 inhibitors
- Pipeline drugs
- Venclexta/Venclyxto (venetoclax; AbbVie/Roche)
BTK inhibitors
- Approved drugs
- Brukinsa (zanubrutinib; BeiGene), Calquence (acalabrutinib; AstraZeneca), Imbruvica (ibrutinib; AbbVie/J&J) and Jaypirca (pirtobrutinib; Lilly)
Future treatment trends
- Key insights summary
Appendix
- KOL details
- KOLs from North America
- KOLs from Europe
KOL Bulletins
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.